Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(18 sites)

United States

City of Hope Medical Center, Duarte, California

University of California, Davis Comprehensive Cancer Center, Sacramento, California

University of California San Diego Moores Cancer Center, San Diego, California

Winship Cancer Institute, Emory University, Atlanta, Georgia

University of Chicago Medical Center, Chicago, Illinois

University of Michigan, Ann Arbor, Michigan

Henry Ford Health System, Detroit, Michigan

Washington University, St Louis, Missouri

Laura and Isaac Perlmutter Cancer Center NYU Langone Health, New York, New York

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

The Christ Hospital Cancer Center, Cincinnati, Ohio

Ohio State University Hospital, Columbus, Ohio

University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Sarah Cannon Research Institute, Nashville, Tennessee

University of Texas Southwestern Medical Center, Dallas, Texas

The University of Texas, MD Anderson Cancer Center, Houston, Texas